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OBJECTIVES This study compares the efficacy of primary angioplasty and systemic thrombolysis with t-PA
in reducing the in-hospital mortality of patients with anterior AMI.
BACKGROUND Controversy still exists about the relative benefit of primary angioplasty over thrombolysis as
treatment for AMI.
METHODS Two-hundred and twenty patients with anterior AMI were randomly assigned in our
institution to primary angioplasty (109 patients) or systemic thrombolysis with accelerated
t-PA (111 patients) within the first five hours from the onset of symptoms.
RESULTS Baseline characteristics were similar in both groups. Primary angioplasty was independently
associated with a lower in-hospital mortality (2.8% vs. 10.8%, p 5 0.02, adjusted odds ratio
0.23, 95% confidence interval 0.06 to 0.85). During hospitalization, patients treated by
angioplasty had a lower frequency of postinfarction angina or positive stress test (11.9% vs.
25.2%, p 5 0.01) and less frequently underwent percutaneous or surgical revascularization
after the initial treatment (22.0% vs. 47.7%, p , 0.001) than did patients treated by t-PA. At
six month follow-up, patients treated by angioplasty had a lower cumulative rate of death
(4.6% vs. 11.7%, p 5 0.05) and revascularization (31.2% vs. 55.9%, p , 0.001) than those
treated by t-PA.
CONCLUSIONS In centers with an experienced and readily available interventional team, primary angioplasty
is superior to t-PA for the treatment of anterior AMI. (J Am Coll Cardiol 1999;33:605–11)
© 1999 by the American College of Cardiology
Controversy still exists about the relative benefit of primary
percutaneous transluminal coronary angioplasty (PTCA)
over systemic thrombolysis for the treatment of acute
myocardial infarction (AMI). Primary PTCA has shown
clinical benefit over thrombolytic therapy in two random-
ized studies (1,2). In the GUSTO IIb study, the mortality of
patients assigned to primary PTCA was not statistically
different from patients assigned to tissue plasminogen acti-
vator (t-PA), although the patients treated by primary
PTCA experienced a modest benefit in the combined
endpoint of death, nonfatal reinfarction and disabling stroke
(3). Recently, a metaanalysis of 10 randomized trials of
primary PTCA versus thrombolysis in AMI that included
2,606 patients, demonstrated a significant reduction of
mortality in patients treated by PTCA at the end of the
study period (4).
The size of the risk area of an occluded coronary artery is
an important determinant of outcome in patients with AMI
(5). Patients with anterior AMI have worse immediate and
long-term prognosis than patients with nonanterior AMI,
who normally have smaller risk areas (6–10). In addition,
data from thrombolytic trials show that patients with large
risk areas benefit most from reperfusion of the infarct
related artery, whereas the benefit of thrombolysis in pa-
tients with small risk areas is usually modest (11). There-
fore, if primary PTCA yields a more rapid and complete
restoration of blood flow through the infarct related artery
than does systemic thrombolysis, the benefit from PTCA
should be more striking in patients with anterior AMI. On
this basis, the purpose of our study was to determine
whether primary PTCA is better than accelerated t-PA in
reducing the in-hospital mortality of patients with anterior
AMI.
METHODS
Patient selection. One-hundred and eighty-nine patients
(86% of the study population) were enrolled in our own
prospective randomized trial (12). The protocol of our trial
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stated that patients who arrived at the emergency depart-
ment with suspected AMI were candidates for recruitment
if chest pain had lasted between 30 min and 5 h without
response to nitrates and the 12-lead electrocardiogram
showed ST elevation of at least 0.2 mV in two or more
contiguous precordial leads. Criteria for exclusion were
contraindications to thrombolysis, left bundle branch block,
age younger than 18 years and females of childbearing age.
The remaining 31 patients (14% of the study population),
who were also randomized and treated in our institution,
belonged to a multicenter trial of primary PTCA versus
accelerated t-PA in AMI (3). They were included in the
present analysis because they exactly fulfilled all the inclu-
sion criteria of our trial.
Randomization and treatment groups. Eligible patients
were given 300 mg of aspirin intravenously unless there was
a known allergy. They were taken to the coronary care unit
and were informed about the protocol which had been
approved of by the hospital institutional review board. An
informed consent was obtained for being included in the
trial. Enrolled patients were randomly allocated to primary
PTCA (group A) or systemic thrombolysis (group B).
Patients randomly assigned to primary PTCA were
immediately taken to the cardiac catheterization laboratory.
In our center there is a continuous availability of a coronary
interventional team. A bolus of 10,000 I.U. of heparin was
administered and small additional boluses if necessary to
achieve an activated clotting time longer than 350 s. The
procedure was started with a right coronary angiography
first in order to assess this artery and the status of the
collateral circulation to the left anterior descending artery
(LAD) (13). Primary PTCA was performed using conven-
tional catheter-balloon technique. Stents were used only for
suboptimal balloon PTCA results or flow-limiting dissec-
tions. An intraaortic balloon pump was inserted in patients
with hemodynamic instability or in patients with large
infarctions when TIMI flow in the LAD was lower than
grade 2 at the end of the procedure. Left ventriculography
was not performed during this procedure. Femoral sheaths
were removed 4 to 8 h after the procedure when the
activated partial-thromboplastin time was lower than 60 s.
Once the sheaths were withdrawn, heparin was restarted
and the dose adjusted aiming for a partial-thromboplastin
time twice the control value during 48 h.
Patients randomly assigned to thrombolysis received
single-chain tissue plasminogen activator (t-PA, alteplase)
as a front-loaded regimen starting with a 15 mg intravenous
bolus, followed by an infusion of 0.75 mg/kg over 30 min
(maximum 50 mg) and then, 0.50 mg/kg over 60 min
(maximum 35 mg). An intravenous bolus of heparin
(5,000 I.U.) was administered simultaneously with alteplase
and was followed by a continuous perfusion of heparin,
initially at 1,000 I.U./h and later adjusted to achieve a
partial-thromboplastin time twice the control value.
Adjunctive pharmacologic therapy followed the standards
of the coronary care unit. Heparin was administered in
patients from both treatment groups for at least 48 h. The
indication of anticoagulation after this period was individ-
ualized to each patient independently of the treatment
group assigned.
Angiographic evaluation. In patients from group A, the
number of diseased vessels (diameter narrowing 50% or
more), the level of LAD occlusion and the TIMI flow in the
LAD at the baseline diagnostic coronary angiography are
reported. The occlusion of the LAD was considered prox-
imal if located before the first well-developed septal branch,
distal if located after the third diagonal branch and mid if
located between these limits. The primary PTCA procedure
was considered successful when the TIMI flow in the LAD
at the end of the procedure was grade 2 or 3 and the residual
stenosis was less than 50 percent. Patients from group B did
not undergo an early coronary catheterization following
thrombolysis unless clinically indicated.
The protocol of our trial encouraged the performance of
a routine predischarge cardiac catheterization with coronary
angiography and left ventriculography for patients from
both treatment groups to assess the patency and residual
stenosis of the LAD and the left ventricular ejection fraction
(LVEF). However, the indication of revascularization was
established on clinical bases.
Clinical course. The primary objective of this study was to
examine in-hospital death. Secondary objectives were to
examine the occurrence of nonfatal reinfarction, post-
infarction ischemia and the need for revascularization pro-
cedure after the initial treatment (primary PTCA or t-PA).
Reinfarction was defined as the recurrence of ischemic chest
pain of at least 30 min duration with ST segment elevation
of a minimum of 0.1 mV over the previous ST segment in
two contiguous leads and an enzyme profile consistent with
the diagnosis. Postinfarction angina was defined as the
recurrence of ischemic chest pain with electrocardiographic
changes without fulfilling criteria for reinfarction. Post-
infarction ischemia was defined as the presence of sponta-
neous postinfarction angina and/or positive stress test before
discharge. Independently of the treatment group assigned,
severe ischemic symptoms that persisted or recurred despite
optimal pharmacologic therapy were treated by emergency
coronary angiography and revascularization. The in-hospital
and sixth month follow-up cumulative rates of death,
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CK-MB 5 MB fraction of creatine kinase
LAD 5 left anterior descending coronary artery
PTCA 5 percutaneous transluminal coronary
angioplasty
t-PA 5 tissue plasminogen activator
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nonfatal reinfarction, postinfarction ischemia and revascu-
larization were analyzed. The sixth month follow-up was
accomplished by personal interview or by telephone call if
the personal interview was not feasible.
Statistical analysis. All analyses adhered to the intention
to primary treatment principle. Differences in means be-
tween both groups were analyzed with the Student t-test for
unpaired observations. For comparisons of proportions be-
tween groups, the Chi-square test was used, except in cases
whose expected values were less than 5 in which case we
used the Fisher exact test. Multivariate analysis for mortality
was performed by multiple logistic regression. Odds ratios
were expressed together with 95% confidence intervals. All
results were analyzed using a two-sided significance level of
0.05, but all p values ,0.20 are reported. Data analyses were
performed by using the statistical software SPSS 7.5 for
Windows 95, from SPSS Inc., 1996.
RESULTS
Study population. Two-hundred and twenty patients with
anterior wall AMI less than five hours from the onset of
symptoms were randomized in our institution from July
1991 to May 1996. One-hundred and nine patients were
assigned to primary PTCA (group A) and 111 patients were
assigned to thrombolysis with t-PA (group B). In this
period, 632 patients with anterior AMI were admitted to
our coronary care unit. Among these, 67 patients who were
admitted in the first five hours of evolution were referred for
primary PTCA without having been enrolled in the trial
because of having exclusion criteria, patient’s refusal or
physician’s preference.
The baseline clinical characteristics of the two groups are
summarized in Table 1. The median elapsed time between
the onset of symptoms and hospital admission was 120 min
in both groups (25th and 75th percentiles 5 85–180 min in
group A and 80–175 min in group B, p 5 NS).
In-hospital therapy. Of the 109 patients randomly as-
signed to primary PTCA, 1 patient (1%) had a normal
coronary angiogram, 66 patients (60%) had single-vessel
disease, 25 patients (23%) had double-vessel disease and the
other 17 (16%) had triple-vessel disease. The level of LAD
occlusion was located in the proximal segment in 40 patients
(37%), in the mid segment in 64 patients (59%) and in the
distal segment in 4 patients (4%). The baseline TIMI flow
in the LAD was grade 0 in 87 patients (80%), grade 1 in 7
patients (6%), grade 2 in 11 patients (10%) and grade 3 in
4 patients (4%). Of the 94 patients with an occluded LAD
(TIMI flow grades 0 or 1), 31 patients (33%) had collateral
circulation to the LAD.
One-hundred and seven patients from group A (98%)
underwent primary PTCA of the LAD. One patient had a
coronary anatomy unsuitable for PTCA and was treated by
coronary artery bypass grafting (CABG). The other patient
had a normal coronary angiogram at baseline in spite of the
infarction being confirmed by electrocardiogram and en-
zyme profile. The median elapsed time from the onset of
symptoms to the first balloon inflation was 197 min (25th
and 75th percentiles 5 150–250 min). The median length
of time from the onset of symptoms to the end of the
primary PTCA procedure was 225 min (25th and 75th
percentiles 5 180–295 min). Fourteen patients (13%)
received 21 stents because of a suboptimal balloon PTCA
result or dissection. In the majority of patients, PTCA was
attempted only to the infarct related artery, but in 3 cases
additional PTCA to another vessel was performed due to
persistent hemodynamic instability. None of the patients
assigned to PTCA had previously received systemic throm-
bolysis. The PTCA procedure was successful in 101 patients
(94.4%) and TIMI grade 3 flow at the end of the procedure
was obtained in 73 patients (68.2%). No patient underwent
emergency CABG because of complications during the
PTCA. Four patients from group A underwent CABG in
the first 72 h after primary PTCA because of extensive
coronary artery disease unfavorable for further percutaneous
revascularization.
All patients from group B received systemic thrombolysis
with t-PA. The median elapsed time from the onset of
symptoms to the start of the t-PA infusion was 150 min
(25th and 75th percentiles 5 105–215 min).
Significant differences between groups A and B were not
found in the administration of aspirin (98% of patients in
both groups), early intravenous betablockers (16% vs. 21%,
p 5 NS), oral betablockers (48% vs. 53%, respectively, p 5
NS), angiotensin-converting-enzyme inhibitors (45% vs.
51%, p 5 NS) and oral anticoagulants (15% vs. 10%, p 5
NS) during hospitalization.
In-hospital course. Two patients from group A who had
the LAD occluded at the basal angiography and one patient
from group B developed a peak serum level of the MB
fraction of creatine kinase (CK-MB) less than twice the
upper limit of normality. In the remaining patients, a typical
Table 1. Baseline Characteristics of the Patients
Group A
n 5 109
Group B
n 5 111
Age, years: median
(25th–75th percentiles)
63 (53–71) 60 (53–74)
Male 91 (84%) 89 (80%)
Smokers 67 (62%) 78 (70%)
Hypercholesterolemia* 23 (21%) 37 (33%)
Hypertension 35 (32%) 43 (39%)
Diabetes Mellitus 13 (12%) 19 (17%)
Previous myocardial infarction 14 (13%) 14 (13%)
Killip class at admission:
Class I 99 (91%) 100 (90%)
Class II 6 (5%) 6 (5%)
Class III 2 (2%) 1 (1%)
Class IV 2 (2%) 4 (4%)
Differences were not statistically significant for any comparison, except for hypercho-
lesterolemia (*p 5 0.04).
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enzyme profile consistent with the diagnosis of AMI was
observed. Table 2 summarizes the adverse clinical events of
patients from both treatment groups that occurred during
hospitalization. Mortality was lower in group A (3 patients
from group A [2.8%] vs. 12 patients from group B [10.8%],
p 5 0.02). In group A the causes of death were cardiogenic
shock (1 patient) and free-wall rupture (2 patients). In
group B they were cardiogenic shock (5 patients), free-wall
rupture (5 patients), hemorragic stroke (1 patient) and
coronary perforation with cardiac tamponade complicating a
PTCA procedure performed due to a reinfarction (1 pa-
tient). The independent effect of primary PTCA on the
reduction of the in-hospital mortality was confirmed after
adjustment for age, sex, hypercholesterolemia, diabetes and
previous infarction (adjusted odds ratio 0.23, 95% confi-
dence interval 0.06 to 0.85, p 5 0.02). Additionally, age
(odds ratio per year of increase 1.06, 95% confidence
interval 1.01 to 1.11, p 5 0.03) and diabetes mellitus (odds
ratio 3.8, 95% confidence interval 1.2 to 12.1, p 5 0.03)
were also independently associated with in-hospital mortal-
ity by stepwise multiple logistic regression.
There were no differences in the occurrence of nonfatal
reinfarction in either group. There were three strokes (two
embolic and one hemorragic stroke) and all of them were in
group B. Group A had a lower frequency of post-infarction
ischemia than group B (11.9% vs. 25.2%, p 5 0.01).
Predischarge cardiac catheterization. Seventy-three pa-
tients from group A (67%) and 77 patients from group B
(69%) underwent a predischarge cardiac catheterization
including coronary angiography and left ventriculography.
The angiographic findings of these patients are summarized
in Table 3. Group A showed a better TIMI flow in the
LAD and a lower diameter stenosis. The left ventricular
ejection fraction was similar in both groups. The proportion
of patients who underwent PTCA of the LAD (excluding
primary PTCA procedures) was significantly lower in group
A than in group B (17 patients [15.6%] vs. 39 [35.1%], p 5
0.001). Group A also had a tendency to undergo CABG less
frequently than group B (7 patients [6.4%] vs. 14 [12.6%],
p 5 0.12). The median length of hospitalization was 15
days in each group (25th and 75th percentiles 5 11–20 days
in group A and 12–19 days in group B, p 5 NS).
Sixth month follow-up. The clinical status was assessed at
the sixth month postinfarction in 190 of the 201 patients
eligible for follow-up, 99 patients from group A and 91
patients from group B. The proportion of missing patients
at the sixth month postinfarction was 5% in group A and 6%
in group B. After discharge, there were no differences in the
occurrence of death (two patients from group A [2.0%] vs.
one patient from group B [1.1%], p 5 NS), nor nonfatal
Table 2. In-Hospital Clinical Events
Group A
n 5 109
Group B
n 5 111 p Value
Major adverse events:
Death 3 (2.8%) 12 (10.8%) 0.02
Non-fatal reinfarction 4 (3.7%) 6 (5.5%) NS
Stroke 0 3 (2.7%) 0.08
Death, reinfarction or stroke 7 (6.4%) 20 (17%) 0.01
Free-wall rupture* 4 (3.7%) 9 (8.1%) 0.16
Minor adverse events:
Bleeding requiring transfusion 3 (2.8%) 4 (3.6%) NS
Post-infarction angina 9 (8.3%) 16 (14.4%) 0.15
Post-infarction ischemia† 13 (11.9%) 28 (25.2%) 0.01
New revascularization procedure: 24 (22.0%) 53 (47.7%) , 0.001
PTCA to the LAD‡ 17 (15.6%) 39 (35.1%) 0.001
CABG§ 7 (6.4%) 14 (12.6%) 0.12
*All free-wall ruptures were proved at autopsy or operation; †Defined as post-infarction angina or positive stress test; ‡In-hospital
PTCA of the LAD after the initial treatment (PTCA or t-PA); §In-hospital CABG after the initial treatment; CABG 5
Coronary artery bypass graft surgery; LAD 5 Left anterior descending coronary artery; PTCA 5 Percutaneous transluminal
coronary angioplasty.
Table 3. Pre-Discharge Cardiac Catheterization
Group A
n 5 73
Group B
n 5 77
p
Value
Level of LAD acute
occlusion*:
NS
Proximal segment 28 (38.3%) 24 (38.1%)
Mid-segment 44 (60.2%) 36 (57.1%)
Distal segment 1 (1.5%) 3 (4.8%)
TIMI flow in the LAD: , 0.001
Grade 0 2 (2.7%) 14 (18.2%)
Grade 1 0 5 (6.5%)
Grade 2 7 (9.6%) 15 (19.5%)
Grade 3 64 (87.7%) 43 (55.8%)
LAD stenosis, %† 31 (20–40) 70 (50–90) , 0.001
LVEF, %† 48 (40–60) 47 (39–60) NS
*The level of LAD acute occlusion could not be determined in 14 patients from group
B; †LVEF and LAD stenosis are presented as median and the 25th and 75th
percentiles; LAD 5 Left anterior descending coronary artery; LVEF 5 Left
ventricular ejection fraction; TIMI 5 Thrombolysis in Myocardial Infarction (trial).
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reinfarction (two patients from group A [2.0%] vs. one
patient from group B [1.1%], p 5 NS). Unstable angina
appeared in five patients from group A and in nine patients
from group B (5.1% vs. 9.9%, p 5 NS). Percutaneous
luminal coronary angioplasty was performed on 11 patients
from group A and 13 patients from group B (11.2% vs.
14.4%, p 5 NS). One patient from group A and three
patients from group B underwent CABG (1% vs. 3.3%, p 5
NS). The cumulative incidence of death, nonfatal reinfarc-
tion and percutaneous or surgical revascularization at the
sixth month postinfarction are presented in Table 4.
DISCUSSION
Our study includes patients with anterior AMI admitted to
our hospital within five hours from the onset of symptoms
and randomly assigned to primary PTCA or systemic
thrombolysis with accelerated t-PA. Patients treated by
primary PTCA experienced a reduction in mortality, recur-
rent ischemia and need for revascularization of the infarct
related artery during the hospital stay. At the six-month
follow up, post discharge adverse events were infrequent and
similar in both groups. The reduction of in-hospital mor-
tality observed in patients treated by primary PTCA was
maintained at six months and the cumulative incidence of
percutaneous or surgical revascularization was also signifi-
cantly lower in the PTCA group. Therefore, in a hospital
committed to mechanical reperfusion, primary PTCA of
the infarct related artery in patients with anterior AMI
offers an immediate clinical advantage over systemic throm-
bolysis with t-PA which is maintained at midterm follow-
up.
Our results apply to a strategy based on initial treatment
with either primary PTCA or t-PA and subsequent addi-
tional revascularization when clinically appropriate. Patients
from both groups were treated by emergency coronary
angiography and revascularization for episodes of severe
ischemic symptoms that persisted or recurred despite opti-
mal pharmacologic therapy. Less severe postinfarction isch-
emia was treated by elective coronary revascularization
during the same hospitalization when indicated. Because a
substantial amount of patients from both groups underwent
coronary revascularization for recurrent ischemia during
hospitalization, this study represents a comparison of two
strategies, rather than a study of the use of primary PTCA
versus thrombolysis alone.
Randomized studies do not ensure the control of poten-
tial confounding variables if the size of the study groups is
not large enough. Small differences in the distribution of
these variables may result in confusion if they are strongly
associated with the response object of the study. Therefore,
we used a multiple logistic regression analysis to confirm the
independent effect of primary PTCA on the reduction of
in-hospital mortality. After adjustment for age, sex, hyper-
cholesterolemia, diabetes and previous infarction, primary
PTCA treatment remained an inverse independent predic-
tor of in-hospital death.
In some previously published studies, patients with ante-
rior AMI seemed to obtain an additional benefit from direct
PTCA over thrombolysis (14–17), but none of them was
specifically designed to study the outcome of patients with
anterior AMI in this setting. We chose to undertake this
study in only one center trying to offer a more uniform
treatment in each group, particularly with respect to the
primary PTCA procedure whose efficacy largely relies on
the experience of the center (18). The angiographic success
rate of primary PTCA in the present study was 94%. The
success rate of PTCA in this study was similar to other
randomized trials (1–3,19) and some observational series
(20–23). Whether or not the reduction in mortality ob-
served in the present study could be accomplished in
hospitals with less experience or less commitment to pri-
mary PTCA remains to be seen. The absence of added
benefit of primary PTCA over systemic thrombolysis in
patients with anterior AMI observed in the Gusto IIb trial
(24) might reflect the relatively small experience in primary
PTCA of some participating centers.
Some concern has been raised about the time delay linked
to primary angioplasty (20). The median elapsed time from
the onset of symptoms to the hospital admission was
120 min in both groups. The median length of time from
the onset of symptoms to the initiation of treatment was
197 min in group A (first balloon inflation) and 150 min in
group B (start of the t-PA infusion). Estimations of the
time to reperfusion could not be reliably determined in both
groups. In group A, the median elapsed time from the onset
of symptoms to the end of the primary PTCA procedure
was 225 min, although the time to the end of the primary
PTCA procedure overestimates the time to the restoration
of flow to the infarct related artery. In group B, patients did
not undergo early coronary angiography following throm-
bolysis. Since previous studies have shown that patency rates
higher than 80% do not occur before 90 min of the start of
front-loaded t-PA (25–27), the longer time that was nec-
essary to start the primary PTCA procedure may have been
compensated for a more rapid restoration of blood flow once
the treatment started.
In previous trials (1,3,19) patients treated by primary
PTCA had a shorter length of hospitalization than patients
treated by thrombolysis. In our study, the hospital stay was
similarly long in both groups. This was due to the fact that
our study protocol stated that stress tests should not be
Table 4. Cumulative Sixth Month Adverse Clinical Events*
Group A Group B p Value
Death 5 (4.6%) 13 (11.7%) 0.05
Nonfatal reinfarction 6 (5.5%) 8 (7.2%) NS
Revascularization† 34 (31.2%) 62 (55.9%) , 0.001
*The in-hospital events are included in these figures. †PTCA or CABG in the first
6 months after the initial treatment. Abbreviations as in Table 2.
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performed before the ninth day postinfarction, as well as
encouraged the performance of a routine predischarge
cardiac catheterization for patients from both treatment
groups to assess the status of the infarct related artery and
the LVEF. The infarct related artery was more frequently
patent and the diameter stenosis was smaller in patients
treated by primary PTCA. As in some previous trials (1,19),
the LVEF was similar in survivors from both groups.
Limitations of the study. The study protocol did not call
for a baseline assessment of the left ventricular ejection
fraction, but indirect data such as the equal prevalence of
previous myocardial infarction, the similar distribution in
Killip class and the random assignment of the two groups
suggest that it was probably similar in both groups. The
proportion of patients who were in cardiogenic shock or
clinical heart failure on admission was lower than the
expected which explains in part the low overall mortality of
our study population. The difficulty in obtaining an in-
formed consent from the sickest patients, the urgency to
treat them and the physician’s preference for using primary
PTCA for patients in cardiogenic shock or heart failure may
explain the low proportion of these patients who were
enrolled in this trial, as occurred in earlier randomized
studies (28). Additionally, the exclusion from this trial of
patients ineligible for thrombolysis, who frequently have a
high risk clinical profile (29,30), may have contributed to
the low overall mortality. Thus, the 2.8% in-hospital mor-
tality rate of the primary PTCA arm of this trial contrasts
with the 16.4% mortality of the whole anterior AMI
population treated by primary PTCA within 6 h of symp-
toms in our center in a similar period, who had a 16%
prevalence of shock at admission and frequently had con-
traindications to thrombolytics (13).
The proportion of patients receiving early intravenous
beta-adrenergic blocking agents was low in both treatment
groups which might explain in part the high rate of free-wall
rupture observed in our study. Previous thrombolytic trials
have demonstrated the beneficial effect of early intravenous
betablockade on the reduction of myocardial rupture.
This study had a long inclusion period and there have
been advances in the treatment of AMI, especially in
interventional practice, since this study first began. Al-
though no thrombolytic regimen has been clinically proven
to be superior to front-loaded t-PA, new promising throm-
bolytics and combinations of these with glycoprotein IIb/
IIIa receptor antagonists or antithrombin agents are being
evaluated. On the other hand, the wider use of stents and
the greater experience in primary PTCA procedures, the
improvement in the PTCA catheter technology and the use
of adjunctive pharmacological therapy like glycoprotein
IIb/IIIa antagonists might improve the result of PTCA in
patients with AMI. However, while no pharmacological
regimen shows a significant clinical superiority over front-
loaded t-PA, primary PTCA may be considered as the best
therapeutic choice for the treatment of anterior wall AMI in
centers with an experienced and readily available interven-
tional team.
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